Cochrane · systematic review · CD011742
Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease
Abdul Wahid, SF, Law, ZK, Ismail, NA, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
NeuromuscularAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
2
Included studies
NR
No studies 2 · 28.6%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
BM‐MSC compared to no treatment for amyotrophic lateral sclerosis/motor neuron disease
Population: people with probable or definite amyotrophic lateral sclerosis/motor neuron disease (treated with riluzole)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Functional impairment, assessed using a functional rating scale (change from baseline to 6 months): mean change in ALSFRS‐R score BM‐MSC vs no treatment | no estimate extracted | 1 study · 56 participants | Low Downgraded: risk of bias, imprecision |
Functional impairment, assessed using a functional rating scale (change from baseline to 12 months) BM‐MSC vs no treatment | no estimate extracted | NR | No studies |
Muscle strength: manual muscle testing (mean change from baseline to 12 months) BM‐MSC vs no treatment | no estimate extracted | NR | No studies |
Respiratory function: change in FVC% (mean change from baseline to 12 months) BM‐MSC vs no treatment | no estimate extracted | 1 study · 56 participants | Low Downgraded: risk of bias, imprecision |
Overall survival BM‐MSC vs no treatment | RR 1.07 [0.94, 1.22] | 1 study · 64 participants | Low Downgraded: risk of bias, imprecision |
Adverse events, total BM‐MSC vs no treatment | RR 0.86 [0.62, 1.19] | 1 study · 64 participants | Low Downgraded: risk of bias, imprecision |
Serious adverse events BM‐MSC vs no treatment | RR 0.47 [0.13, 1.72] | 1 study · 64 participants | Low Downgraded: risk of bias, imprecision |